Landscape → Rare Disease

Hemophilia Clinical Trial Landscape

Data updated: May 20, 2026

287 clinical trials tracked since 2008

Hemophilia is being studied across 287 clinical trials registered since 2008, with 72 programs currently active. The competitive pipeline includes 33 active Phase 3 trials, 20 active Phase 2 trials, and 22 active Phase 1 trials. Top industry sponsors include Pfizer, Roche, CSL Behring.

72 active

287 total (since 2008)

Phase 1 Active

84 total

Phase 2 Active

72 total

Phase 3 Active

126 total

Phase 4 Active

50 total

Top Industry Sponsors

Sorted by active Active Done Failed

Pfizer 7 18 2

Roche 6 8 1

CSL Behring 4 13 2

Swedish Orphan Biovitrum 4 1 1

Suzhou Alphamab Co., Ltd. 4 1 0

+ 10 more sponsors — see full table below

Featured Phase 3 Trials

NCT05568719 RECRUITING

Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively

Pfizer n=173

NCT03861273 ACTIVE NOT RECRUITING

A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia B

Pfizer n=51

NCT07080905 RECRUITING

Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B

CSL Behring n=20

NCT07416604 RECRUITING

A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A

Hoffmann-La Roche n=360

NCT07416526 RECRUITING

A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A

Hoffmann-La Roche n=126

+ 121 more Phase 3 trials — see full database below

Hemophilia — Trials Started by Year (last 10 years)

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

2026

TheraRadar.com

Full Trial Database

Complete sponsor table, every trial across all phases, plus competitive analytics. Sortable, filterable, exportable for Pro users.

Top Sponsors (all-time)

Pfizer

Roche

CSL Behring

Swedish Orphan Biovitrum

Suzhou Alphamab Co., Ltd.

Sanofi

Biocad

Octapharma

Jiangsu Gensciences lnc.

BioMarin Pharmaceutical

Active Trials by Phase

Phase 1

Phase 2

Phase 3

Phase 4

Enrollment Size Distribution

1-50

192

51-200

201-500

501-1k

1k+

All Industry Sponsors

Sorted by active Active Done Failed

Pfizer 7 18 2

Roche 6 8 1

CSL Behring 4 13 2

Swedish Orphan Biovitrum 4 1 1

Suzhou Alphamab Co., Ltd. 4 1 0

Sanofi 3 2 0

Biocad 3 0 0

Octapharma 2 7 1

Jiangsu Gensciences lnc. 2 5 0

BioMarin Pharmaceutical 2 3 1

Genzyme, a Sanofi Company 2 4 0

Gritgen Therapeutics Co., Ltd. 2 0 0

Shanghai Xinzhi BioMed Co., Ltd. 2 0 0

Baxalta now part of Shire 1 24 5

Bayer 1 20 3

NCT05568719 RECRUITING

Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively

Pfizer n=173

NCT03861273 ACTIVE NOT RECRUITING

A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia B

Pfizer n=51

NCT07080905 RECRUITING

Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B

CSL Behring n=20

NCT07416604 RECRUITING

A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A

Hoffmann-La Roche n=360

NCT07416526 RECRUITING

A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A

Hoffmann-La Roche n=126

NCT05611801 RECRUITING

A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B

Pfizer n=100

NCT07285460 RECRUITING

A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B

Sanofi n=85

NCT04563520 RECRUITING

SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis

Emory University n=5

NCT06738485 ACTIVE NOT RECRUITING

Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII Products

CSL Behring n=60

NCT06922045 RECRUITING

Phase III Clinical Trial of STSP-0601 for Injection in Hemophilia Patients

Jiangsu BioJeTay Biotechnology Co., Ltd. n=40

NCT07545395 RECRUITING

Safety of KN057 Prophylaxis in Patients With Haemophilia A or B

Suzhou Alphamab Co., Ltd. n=70

NCT05145127 RECRUITING

Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors

Pfizer n=245

NCT04431726 ACTIVE NOT RECRUITING

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors

Hoffmann-La Roche n=55

NCT05203679 ACTIVE NOT RECRUITING

Evaluation of the Safety and Efficacy of Hemophilia B Gene Therapy Drug

Shanghai Xinzhi BioMed Co., Ltd. n=32

NCT06224907 ACTIVE NOT RECRUITING

Phase 3 Study for Efficacy and Safety Outcomes Data in Japanese Patients With Severe Hemophilia A

BioMarin Pharmaceutical n=6

NCT06003387 RECRUITING

Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)

CSL Behring n=35

NCT06111638 RECRUITING

Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs

Shanghai Xinzhi BioMed Co., Ltd. n=55

NCT07439055 ACTIVE NOT RECRUITING

Real-World Joint Outcomes After Selective Transition to Low-Dose Emicizumab in Pediatric Hemophilia A

Chulalongkorn University n=18

NCT05662319 ACTIVE NOT RECRUITING

A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia

Sanofi n=91

NCT06399289 ACTIVE NOT RECRUITING

Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Chinese Subjects With Hemophilia B Previously Treated With FIX Therapy

CSL Behring n=23

NCT03754790 ACTIVE NOT RECRUITING

Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX

Genzyme, a Sanofi Company n=281

NCT06833983 RECRUITING

To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A

Gritgen Therapeutics Co., Ltd. n=50

NCT06700096 RECRUITING

An Open-Label, Comparative Study of the Efficacy, Safety and Pharmacodynamics of Single Dose of ANB-002 in Patients With Hemophilia B

Biocad n=24

NCT05817812 ACTIVE NOT RECRUITING

A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog Alfa

Swedish Orphan Biovitrum n=93

NCT06569108 ACTIVE NOT RECRUITING

Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B Without Inhibitors

Suzhou Alphamab Co., Ltd. n=125

NCT06312475 ACTIVE NOT RECRUITING

Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B With Inhibitors

Suzhou Alphamab Co., Ltd. n=53

NCT04370054 ACTIVE NOT RECRUITING

Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A Adults

Pfizer n=77

NCT03974113 ACTIVE NOT RECRUITING

Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B

Genzyme, a Sanofi Company n=32

NCT04644575 ACTIVE NOT RECRUITING

Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A

Bioverativ, a Sanofi company n=261

NCT06938659 NOT YET RECRUITING

Low Dose Emicizumab vs Low Dose Factor VIII in Prophylaxis in Hemophilia A Patients

Dhaka Medical College n=20

NCT06738901 NOT YET RECRUITING

An Open-label Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of SKP-0141 for the Treatment and Prophylaxis in Severe Hemophilia a Patients

SK Plasma Co., Ltd. n=55

NCT06136507 NOT YET RECRUITING

Study of Efficacy and Safety of FRSW107 in Pediatric Patients With Severe Hemophilia A

Jiangsu Gensciences lnc. n=76

NCT06142552 RECRUITING

Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein

Jiangsu Gensciences lnc. n=120

NCT03315455 COMPLETED

Efficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A Participants

Hoffmann-La Roche n=85

NCT03569891 COMPLETED

HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients

CSL Behring n=67

NCT04158648 COMPLETED

A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII Inhibitors

Hoffmann-La Roche n=73

NCT05147662 COMPLETED

A Study to Learn How Safe the Study Treatment BAY94-9027 is and How it Affects the Body in Previously Treated Children Aged 7 to Less Than 12 Years With Severe Hemophilia A, a Genetic Bleeding Disorder That is Caused by the Lack of a Protein Called Clotting Factor 8 (FVIII) in the Blood

Bayer n=36

NCT03587116 COMPLETED

A Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%)

Pfizer n=212

NCT04323098 COMPLETED

Study to Evaluate the Efficacy and Safety of Valoctocogene Roxaparvovec, With Prophylactic Steroids in Hemophilia A

BioMarin Pharmaceutical n=22

NCT04759131 COMPLETED

Safety, Efficacy and PK of BIVV001 in Pediatric Patients With Hemophilia A

Bioverativ, a Sanofi company n=74

NCT02615691 COMPLETED

A Study of PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Young Children With Severe Hemophilia A

Baxalta now part of Shire n=120

NCT05695391 TERMINATED

A Phase 3 Study of the Safety and Efficacy of Coagulation Factor VIIa (Recombinant) for the Prevention of Excessive Bleeding in Patients With Congenital Hemophilia A or B With Inhibitors to Factor VIII or IX Undergoing Elective Major Surgical Procedures SCOPE HIM

Laboratoire français de Fractionnement et de Biotechnologies n=2

NCT00868530 COMPLETED

Study Evaluating On-Demand Treatment Of Xyntha In Chinese Subjects

Pfizer n=53

NCT03938792 COMPLETED

Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B

Pfizer n=189

NCT05707351 COMPLETED

A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A

Takeda n=37

NCT03370913 COMPLETED

Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients (BMN 270-301)

BioMarin Pharmaceutical n=144

NCT06568302 TERMINATED

The Long-term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who Completed a Sponsored SerpinPC Clinical Trial

ApcinteX Ltd n=15

NCT06297486 WITHDRAWN

Study of a Gene Therapy Treatment for Hemophilia A

Spark Therapeutics, Inc.

NCT04580407 COMPLETED

Study of TAK-672 in Participants With Acquired Hemophilia A

Takeda n=5

NCT03855280 COMPLETED

Evaluation of a Recombinant Factor IX Product, APVO101, in Previously-Treated Pediatric Patients With Hemophilia B

Medexus Pharma, Inc. n=21

NCT04030052 WITHDRAWN

Emicizumab PUPs and Nuwiq ITI Study

Emory University

NCT04456387 COMPLETED

An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.

Zhengzhou Gensciences Inc n=119

NCT06137092 COMPLETED

rFVIII-Fc (Produced by AryoGen Pharmed Co.) Pharmacokinetic Study

AryoGen Pharmed Co. n=50

NCT01580293 COMPLETED

A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A

Bayer n=145

NCT03392974 COMPLETED

Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients at a Dose of 4E13 vg/kg

BioMarin Pharmaceutical n=1

NCT04845399 COMPLETED

Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A

Zhengzhou Gensciences Inc n=101

NCT04303559 TERMINATED

The Hemophilia Inhibitor Prevention Trial

Margaret Ragni n=1

NCT04303572 TERMINATED

The Hemophilia Inhibitor Eradication Trial

Margaret Ragni n=1

NCT02764489 COMPLETED

FEIBA Reconstitution Volume Reduction and Faster Infusion Study (FEIBA STAR)

Baxalta now part of Shire n=45

NCT03549871 COMPLETED

A Study of Fitusiran in Severe Hemophilia A and B Patients Previously Receiving Factor or Bypassing Agent Prophylaxis

Genzyme, a Sanofi Company n=80

NCT03020160 COMPLETED

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Given Every 4 Weeks in Participants With Hemophilia A

Hoffmann-La Roche n=48

NCT02847637 COMPLETED

A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors

Hoffmann-La Roche n=152

NCT02053792 COMPLETED

A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B

CSL Behring n=97

NCT00759655 TERMINATED

Study Evaluating The Efficacy And Safety Of Xyntha In Children Less Than 6 Years Of Age

Wyeth is now a wholly owned subsidiary of Pfizer n=1

NCT02234323 COMPLETED

An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Previously Untreated Males With Severe Hemophilia A

Bioverativ, a Sanofi company n=108

NCT03417245 COMPLETED

A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors

Genzyme, a Sanofi Company n=120

NCT03417102 COMPLETED

A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors

Genzyme, a Sanofi Company n=60

NCT02234310 COMPLETED

Study to Determine the Safety and Efficacy of rFIXFc in Previously Untreated Males With Severe Hemophilia B

Bioverativ, a Sanofi company n=33

NCT02448680 COMPLETED

A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa

Laboratoire français de Fractionnement et de Biotechnologies n=25

NCT02548143 COMPLETED

LR769 in Congenital Hemophilia Patients With Inhibitors Undergoing Elective Surgery or Invasive Procedures

Laboratoire français de Fractionnement et de Biotechnologies n=12

NCT04489537 TERMINATED

Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Hemophilia A or B

Catalyst Biosciences n=18

NCT02172950 COMPLETED

An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A

CSL Behring n=246

NCT02895945 TERMINATED

BAX 802 in CHA With Inhibitors

Baxalta now part of Shire n=8

NCT02622321 COMPLETED

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors

Hoffmann-La Roche n=113

NCT03191799 COMPLETED

A Study to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients With Inhibitors

Hoffmann-La Roche n=195

NCT02795767 COMPLETED

A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors

Hoffmann-La Roche n=88

NCT02585960 COMPLETED

BAX 855 PK-guided Dosing

Baxalta now part of Shire n=135

NCT01913405 COMPLETED

Phase 3 Efficacy and Safety Study of BAX 855 in Severe Hemophilia A Patients Undergoing Surgical Procedures

Baxalta now part of Shire n=30

NCT01376700 TERMINATED

Early Prophylaxis Immunologic Challenge (EPIC) Study

Baxalta now part of Shire n=22

NCT01945593 COMPLETED

BAX 855 Continuation

Baxalta now part of Shire n=218

NCT02210091 COMPLETED

BAX 855 Pediatric Study

Baxalta now part of Shire n=75

NCT01736475 COMPLETED

Study Investigating a PEGylated Recombinant Factor VIII (BAX 855) for Hemophilia A (PROLONG-ATE Study)

Baxalta now part of Shire n=159

NCT01286779 COMPLETED

BAX 326 (rFIX) Continuation Study

Baxalta now part of Shire n=117

NCT01488994 COMPLETED

BAX 326 Pediatric Study

Baxalta now part of Shire n=23

NCT01174446 COMPLETED

Pivotal Study (Pharmacokinetics, Efficacy, Safety) of BAX 326 (rFIX) in Hemophilia B Patients

Baxalta now part of Shire n=86

NCT00851721 COMPLETED

Efficacy and Safety Study of Prophylactic Versus On-Demand Treatment With Feiba NF in Subjects With Hemophilia A or B and a High Titer Inhibitor

Baxalta now part of Shire n=52

NCT01507896 COMPLETED

BAX 326 Surgery Study in Hemophilia B Patients

Baxalta now part of Shire n=30

NCT01434511 TERMINATED

Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Congenital Hemophilia A

Baxalta now part of Shire n=1

NCT01178294 COMPLETED

Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A

Baxalta now part of Shire n=29

NCT01757405 COMPLETED

Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen

Baxalta now part of Shire n=40

NCT00768287 COMPLETED

Study of Recombinant Factor IX Product, IB1001, in Subjects With Hemophilia B

Medexus Pharma, Inc. n=77

NCT01271868 TERMINATED

Study of Recombinant Factor IX Product, IB1001, in Previously Treated Pediatric Subjects With Hemophilia B

Medexus Pharma, Inc. n=9

NCT03935334 COMPLETED

Clinical Trial Comparing a Biosimilar Eptacog Alfa With Novoseven, in Patients With Hemophilia With Inhibitors

AryoGen Pharmed Co. n=48

NCT01992549 COMPLETED

Study to Investigate Immunogenicity, Efficacy and Safety of Treatment With Human-cl rhFVIII

Octapharma n=48

NCT01712438 COMPLETED

Human Cell Line-derived Recombinant Factor VIII (Human-cl-rhFVIII) in Previously Untreated Patients

Octapharma n=110

NCT02954575 COMPLETED

Clinical Study to Investigate the PK, Efficacy, and Safety of Wilate in Patients With Severe Hemophilia A

Octapharma n=57

NCT03376516 COMPLETED

Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Wilate in Previously Treated Paediatric Patients With Severe Haemophilia A

Octapharma n=11

NCT01181128 COMPLETED

Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Subjects With Severe Hemophilia A

Bioverativ Therapeutics Inc. n=165

NCT01458106 COMPLETED

Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Pediatric Subjects With Hemophilia A

Bioverativ Therapeutics Inc. n=71

NCT01027364 COMPLETED

Study of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Participants With Hemophilia B

Bioverativ Therapeutics Inc. n=123

NCT01440946 COMPLETED

Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in Previously Treated Pediatric Participants With Hemophilia B

Bioverativ Therapeutics Inc. n=30

NCT01425723 COMPLETED

Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia B

Bioverativ Therapeutics Inc. n=120

NCT02502149 COMPLETED

Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale

Bioverativ Therapeutics Inc. n=24

NCT01454739 COMPLETED

Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A

Bioverativ Therapeutics Inc. n=240

NCT01775618 COMPLETED

Safety and Efficacy of BAY94-9027 in Previously Treated Male Children With Haemophilia A

Bayer n=73

NCT02306694 COMPLETED

Prospective Biomarkers of Bone Metabolism in Hemophilia A

Oregon Health and Science University n=16

NCT01341912 COMPLETED

Study to Investigate the Long-term Efficacy and Safety of Human-cl rhFVIII in Previously Treated Patients (PTPs)

Octapharma n=3

NCT03815318 COMPLETED

Evaluation of SCT800 in Prophylaxis Therapy on Previous Treated Patients With Severe Hemophilia A

Sinocelltech Ltd. n=73

NCT02484638 TERMINATED

Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With Inhibitors

CSL Behring n=25

NCT02196207 WITHDRAWN

Hemophilia Inhibitor Clinical Trials (INHIBIT) Platform

Margaret Ragni

NCT01445197 TERMINATED

Study of Biostate for Treatment of Children With Hemophilia A Complicated by Antibody Development

CSL Behring n=1

NCT01125813 COMPLETED

Efficacy and Safety Study of Human-cl rhFVIII in PTPs With Severe Hemophilia A

Octapharma n=32

NCT01229007 COMPLETED

Study of Biostate® in Children With Hemophilia A

CSL Behring n=35

NCT02020369 COMPLETED

Phase III Study of Coagulation FVIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors

rEVO Biologics n=27

NCT02093897 COMPLETED

Pharmacokinetic, Efficacy, and Safety Study of Recombinant Factor VIII Single Chain (rVIII-SingleChain) in Children With Severe Hemophilia A

CSL Behring n=84

NCT01233258 COMPLETED

A Trial to Compare Prophylaxis Therapy to On-demand Therapy With a New Full Length Recombinant FVIII in Patients With Severe Hemophilia A

Bayer n=80

NCT01029340 COMPLETED

Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A

Bayer n=74

NCT01405742 TERMINATED

Hemophilia Adult Prophylaxis Study: Factor VIII in Severe Hemophilia A

University of Pittsburgh n=4

NCT02048111 WITHDRAWN

Study of Recombinant Factor IX Product, IB1001, in Previously Treated Subjects With Hemophilia B

Cangene Corporation

NCT01486927 COMPLETED

An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A

CSL Behring n=175

NCT01496274 COMPLETED

A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B

CSL Behring n=63

NCT01662531 COMPLETED

A Safety, Efficacy and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Children With Hemophilia B

CSL Behring n=27

NCT01625390 COMPLETED

A Phase 2/ 3 Trial to Evaluate the Efficacy and Safety of BAY86-6150

Bayer n=10

NCT01335061 COMPLETED

Study To Compare On-Demand Treatment To A Prophylaxis Regimen Of BeneFIX In Subjects With Moderately Severe to Severe Hemophilia B

Pfizer n=25

NCT00623480 COMPLETED

Trial to Evaluate the Effect of Secondary Prophylaxis With rFVIII Therapy in Severe Hemophilia A Adult and/or Adolescent Subjects Compared to That of Episodic Treatment

Bayer n=84

NCT00866606 COMPLETED

Study Evaluating On-Demand Treatment With BeneFIX In Chinese Subjects

Wyeth is now a wholly owned subsidiary of Pfizer n=35

NCT03307980 ACTIVE NOT RECRUITING

Long-term Safety and Efficacy Study and Dose-Escalation Substudy of PF 06838435 in Individuals With Hemophilia B

Pfizer

NCT07548411 ACTIVE NOT RECRUITING

To Evaluate the Safety and Efficacy of GS1191-0445 Injection in the Treatment of Severe Hemophilia A

Gritgen Therapeutics Co., Ltd.

NCT05987449 RECRUITING

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A

Hoffmann-La Roche

NCT07226206 RECRUITING

A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A

Hoffmann-La Roche

NCT03588299 ACTIVE NOT RECRUITING

Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a "Shuttle"

Bayer

NCT06379789 RECRUITING

A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B

Regeneron Pharmaceuticals

NCT01687608 ACTIVE NOT RECRUITING

Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With Hemophilia B

Baxalta now part of Shire

NCT05345197 ACTIVE NOT RECRUITING

Emicizumab in Patients With Acquired Hemophilia A

University of Washington

NCT06611436 RECRUITING

BeCoMe-9: A Clinical Study of BE-101 for the Treatment of Adults With Moderately Severe or Severe Hemophilia B

Be Biopharma

NCT04684940 ACTIVE NOT RECRUITING

Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active or Prior Inhibitors

BioMarin Pharmaceutical

NCT06120582 RECRUITING

Study of the Safety, Pharmacodynamics and Efficacy of ANB-002 in Patients With Hemophilia B (SAFRAN)

Biocad

NCT06185335 ACTIVE NOT RECRUITING

A Trial of the Safety and Efficacy of Single-Dose Administration of ANB-010 in Subjects With Hemophilia A

Biocad

NCT03001830 ACTIVE NOT RECRUITING

Gene Therapy for Haemophilia A.

University College, London

NCT05641610 RECRUITING

A Study to Evaluate the Safety and Efficacy of ZS801 in Adult Hemophilia B Patients

Institute of Hematology & Blood Diseases Hospital, China

NCT06747416 NOT YET RECRUITING

KN057 Multiple Dose Study in Patients with Hemophilia a or Hemophilia B with or Without Inhibitors

Suzhou Alphamab Co., Ltd.

NCT04676048 RECRUITING

ASC618 Gene Therapy in Hemophilia A Patients

ASC Therapeutics

NCT03061201 COMPLETED

A Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 (PF-07055480) in Subjects With Severe Hemophilia A

Pfizer

NCT03370172 COMPLETED

A Study of BAX 888 in Male Adults With Severe Hemophilia A

Baxalta now part of Shire

NCT03520712 TERMINATED

Gene Therapy Study in Severe Hemophilia A Patients With Antibodies Against AAV5

BioMarin Pharmaceutical

NCT05789537 TERMINATED

A Study of SerpinPC in Participants with Hemophilia B (HemB) with Inhibitors

ApcinteX Ltd

NCT05789524 TERMINATED

The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B

ApcinteX Ltd

NCT04046848 TERMINATED

Safety and Pharmacokinetics of Subcutaneous Injection of OCTA101 in Adult Patients With Severe Hemophilia A

Octapharma

NCT04073498 COMPLETED

The Safety and Tolerability of SerpinPC in Healthy Men and in Men with Severe Blood Disorders (haemophilia a and B)

ApcinteX Ltd

NCT06289166 COMPLETED

Safety and Efficacy of STSP-0601 in Adult Patients with Hemophilia a or B with Inhibitor

Staidson (Beijing) Biopharmaceuticals Co., Ltd

NCT05421429 COMPLETED

KN057 Multiple Dose Study in Moderately Severe to Severe Hemophilia

Suzhou Alphamab Co., Ltd.

NCT03003533 COMPLETED

A Gene Transfer Study for Hemophilia A

Spark Therapeutics, Inc.

NCT05027230 COMPLETED

A Safety and Efficacy Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor

Staidson (Beijing) Biopharmaceuticals Co., Ltd

NCT04541628 TERMINATED

Safety & Efficacy of Encapsulated Allogeneic FVIII Cell Therapy in Haemophilia A

Eli Lilly and Company

NCT06010953 COMPLETED

SS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment

Jiangsu Gensciences lnc.

NCT03489291 COMPLETED

Dose Confirmation Trial of AAV5-hFIXco-Padua

CSL Behring

NCT02554773 COMPLETED

An Open-label Extension Study of an Investigational Drug, Fitusiran, in Patients With Moderate or Severe Hemophilia A or B

Genzyme, a Sanofi Company

NCT05619926 COMPLETED

Safety and Efficacy of STSP-0601 in Adult Patients With Hemophilia A or B Without Inhibitor

Staidson (Beijing) Biopharmaceuticals Co., Ltd

NCT05164471 TERMINATED

Phase 1/2 Dose Confirmation Study of FLT180a in Hemophilia B

Spur Therapeutics

NCT03641703 TERMINATED

A Long-Term Follow-Up Study of Haemophilia B Patients Who Have Undergone Gene Therapy

Spur Therapeutics

NCT05265286 COMPLETED

A Study of Repeat Dosing of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection

Jiangsu Gensciences lnc.

NCT04188639 COMPLETED

Emicizumab in Acquired Hemophilia A

GWT-TUD GmbH

NCT03369444 TERMINATED

A Factor IX Gene Therapy Study (FIX-GT)

University College, London

NCT02396342 COMPLETED

Trial of AAV5-hFIX in Severe or Moderately Severe Hemophilia B

CSL Behring

NCT04394286 TERMINATED

A Phase 1/2 Study of SHP648, an Adeno-Associated Viral Vector for Gene Transfer in Hemophilia B Subjects

Baxalta now part of Shire

NCT03205163 COMPLETED

A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A)

Bioverativ, a Sanofi company

NCT04548791 TERMINATED

Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders

Catalyst Biosciences

NCT03095287 TERMINATED

Alphanate in Immune Tolerance Induction Therapy

Grifols Therapeutics LLC

NCT04677803 COMPLETED

BT200 in Hereditary Bleeding Disorders

Medical University of Vienna

NCT03407651 COMPLETED

Study of Coagulation Factor VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia A and B

Catalyst Biosciences

NCT03995784 COMPLETED

Study of Next-Generation Recombinant Factor IX Variant in Adult Subjects With Hemophilia B

Catalyst Biosciences

NCT03363321 COMPLETED

PF-06741086 Long-term Treatment in Severe Hemophilia

Pfizer

NCT03597022 TERMINATED

Multiple Escalating Dose Study of BAY1093884 in Adults With Hemophilia A or B With or Without Inhibitors

Bayer

NCT00717626 COMPLETED

Once-A-Day Prophylaxis for Youth and Young Adults With Severe Hemophilia A

The Hospital for Sick Children

NCT02586012 TERMINATED

Weight-based Dosing in Hemophilia A

Craig Seaman

NCT00947193 TERMINATED

Study of Ataluren (PTC124) in Hemophilia A and B

PTC Therapeutics

NCT02484092 COMPLETED

A Gene Therapy Study for Hemophilia B

Pfizer

NCT02974855 COMPLETED

PF-06741086 Multiple Dose Study in Severe Hemophilia

Pfizer

NCT00989196 COMPLETED

Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A

Octapharma

NCT02618915 TERMINATED

Safety and Dose Finding Study of DTX101 (AAVrh10FIX) in Adults With Moderate/Severe to Severe Hemophilia B

Ultragenyx Pharmaceutical Inc

NCT01361126 COMPLETED

A Safety and Efficacy Study of a Recombinant Factor IX in Patients With Severe Hemophilia B

CSL Behring

NCT00994929 COMPLETED

Efficacy and Safety of IL-11 in DDAVP Unresponsive

University of Pittsburgh

NCT00623727 TERMINATED

BAY79-4980 Compared to rFVIII-FS in Previously Treated Patients With Severe Hemophilia A

Bayer

NCT00879541 COMPLETED

Study of a pd vWF/FVIII, Biostate®, in Subjects With Haemophilia A

CSL Behring

NCT03961243 RECRUITING

Lentiviral FIX Gene Therapy

Shenzhen Geno-Immune Medical Institute

NCT03217032 RECRUITING

Lentiviral FVIII Gene Therapy

Shenzhen Geno-Immune Medical Institute

NCT05500807 RECRUITING

Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A

Bleeding and Clotting Disorders Institute Peoria, Illinois

NCT06703606 RECRUITING

A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.

Pfizer

NCT06349473 RECRUITING

A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)

Equilibra Bioscience LLC

NCT06579144 RECRUITING

Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia A

Swedish Orphan Biovitrum

NCT03818763 ACTIVE NOT RECRUITING

Gene Therapy Trial for Platelet Derived Factor VIII Production in Hemophilia A

Medical College of Wisconsin

NCT05709288 RECRUITING

Gene Therapy for Hemophilia B Patients Aged 12-18 Years Old

Institute of Hematology & Blood Diseases Hospital, China

NCT04418414 NOT YET RECRUITING

Hematopoietic Stem Cell Transplantation Gene Therapy for Treatment of Severe Hemophilia A

Expression Therapeutics, LLC

NCT00979238 COMPLETED

Dose-Escalation Study Of A Self Complementary Adeno-Associated Viral Vector For Gene Transfer in Hemophilia B

St. Jude Children's Research Hospital

NCT05493631 COMPLETED

A Phase 1b Study to Assess the Safety, Tolerability, PK and PD of MG1113 in Hemophilia Patient

GC Biopharma Corp

NCT05042440 COMPLETED

Pharmacokinetic Assessment of Standard Half-Life (SHL) FVIII, Extended Half-Life (EHL) FVIII, and Efanesoctocog Alfa (BIVV001) in Severe Hemophilia A

Sanofi

NCT06025552 COMPLETED

Study of TU7710 in Warfarin Anti-coagulated Healthy Male Subjects

TiumBio Co., Ltd.

NCT04747964 COMPLETED

A Safety Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor

Staidson (Beijing) Biopharmaceuticals Co., Ltd

NCT02695160 TERMINATED

Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemophilia B

Sangamo Therapeutics

NCT05265767 COMPLETED

Hematopoietic Stem Cell Transplantation Gene Therapy for Treatment of Severe Hemophilia A

Christian Medical College, Vellore, India

NCT04864743 COMPLETED

A Study to Evaluate the Pharmacokinetics，Safety and Tolerability of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection

Jiangsu Gensciences lnc.

NCT05651061 COMPLETED

A Phase I of SS109 in Hemophilia A or and B With Inhibitors

Jiangsu Gensciences lnc.

NCT05251090 COMPLETED

A Study to Evaluate the Safety and Pharmacokinetic of Recombinant Human Coagulation Factor VIII ，Fc Fusion Protein for Injection

Jiangsu Gensciences lnc.

NCT04878731 COMPLETED

Study to Evaluate Safety and Tolerability of a Single Dose of PF-06741086 in Chinese Adult Participants With Severe Hemophilia

Pfizer

NCT03855696 COMPLETED

A Study to Investigate the Safety, Tolerability, PK and PD of MG1113 in Healthy Subjects and Hemophilia Patients

Green Cross Corporation

NCT04072237 COMPLETED

Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia

Catalyst Biosciences

NCT02060305 TERMINATED

Intra-articular Bevacizumab for Recurrent Hemarthroses at Target Joints With Chronic Hemophilic Synovitis

National Taiwan University Hospital

NCT02716194 COMPLETED

BAX 826 Dose-Escalation Safety Study

Baxalta now part of Shire

NCT00952822 COMPLETED

Pharmacokinetic Study of ADVATE Reconstituted in 2 mL Sterile Water for Injection

Baxalta now part of Shire

NCT02418793 COMPLETED

A Study of a Long-Acting r-Factor 7a (Factor VIIa) in Adult Men With Hemophilia A or B

OPKO Health, Inc.

NCT01599819 COMPLETED

BAX 855 Dose-Escalation Safety Study

Baxalta now part of Shire

NCT01191372 TERMINATED

First-in-Human and Proof-of-Mechanism Study of ARC19499 Administered to Hemophilia Patients

Baxalta now part of Shire

NCT04015492 COMPLETED

Study to Compare How the Body Distributes and Excretes the Drugs Jivi (BAY 94-9027) and Adynovi in Patients With Severe Hemophilia A (Bleeding Disorder Resulting From a Lack of Blood Clotting Factor VIII)

Bayer

NCT01027377 COMPLETED

Study of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Subjects With Severe Hemophilia A

Bioverativ Therapeutics Inc.

NCT02083965 COMPLETED

Pharmacokinetics of rFVIIIFc at Two Vial Strengths

Bioverativ Therapeutics Inc.

NCT00716716 COMPLETED

Phase I/IIa Study of FIXFc in Hemophilia B Patients

Bioverativ Therapeutics Inc.

NCT02035605 COMPLETED

A Phase 1 Study of an Investigational Drug, ALN-AT3SC, in Healthy Volunteers and Hemophilia A or B Patients

Sanofi

NCT03186677 COMPLETED

Dose-escalation Study to Investigate the Safety, PK, and PD of ISU304/CB2679d in Hemophilia B Patients

ISU Abxis Co., Ltd.

NCT03481946 COMPLETED

A Study to Assess Pharmacokinetics and Pharmacodynamics Following Administration of BAY1093884 in Patients With Severe Hemophilia

Bayer

NCT03996486 WITHDRAWN

Study to Test the Safety of an Investigational Drug Given Repeatedly to Adult Men With Severe Hemophilia

Bayer

NCT02919800 COMPLETED

A Single-dose, Dose-escalation Study of a Long-acting MOD-5014 in Healthy Adult Male

OPKO Health, Inc.

NCT03380780 COMPLETED

A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Emicizumab in Healthy Chinese Volunteers

Hoffmann-La Roche

NCT03364998 COMPLETED

BAY94-9027 PK Study Comparing to Another Long Acting Product

Bayer

NCT01620801 TERMINATED

Hemophilia B Gene Therapy With AAV8 Vector

Spark Therapeutics, Inc.

NCT02571569 COMPLETED

A Single Escalating Dose and Multiple Dose Study of BAY 1093884 in Subjects With Severe Hemophilia Types A or B, With or Without Inhibitors

Bayer

NCT01184820 COMPLETED

Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration

Bayer

NCT02506023 COMPLETED

Characterization of Laboratory Response to DDAVP in Adult Hemophilia A Carriers

Emory University

NCT01439971 COMPLETED

Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant (813d) In Adult Subjects With Hemophilia

Catalyst Biosciences

NCT02461992 COMPLETED

Study of PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Male Chinese Subjects With Hemophilia A

Pfizer

NCT02213250 COMPLETED

An Open-Label, Single Dose Pharmacokinetic Study of Benefix (Recombinant Factor IX) in Male Chinese Subjects With Hemophilia B

Pfizer

NCT02483208 COMPLETED

Single Dose Study in Subjects With Severe Hemophilia A Comparing Pharmacokinetic Parameters for BAY81-8973 and Advate

Bayer

NCT01704521 COMPLETED

Viral Kinetics in HCV Clearance in Subjects With Hemophilia

Kenneth Sherman

NCT01921855 COMPLETED

Study of FVIIa Variant BAY86-6150 (B0189) in Subjects With Moderate or Severe Hemophilia Types A or B With or Without Inhibitors

Bayer

NCT01653639 COMPLETED

Comparative Pharmacokinetic Study of Two Different Strengths of BAY14-2222

Bayer

NCT01708564 COMPLETED

A Phase I Safety, Pharmacokinetics and Pharmacodynamics Study of Recombinant Factor VIIa in Adult Patients With Hemophilia A or B

rEVO Biologics

NCT01579903 COMPLETED

Relative Bioavailability Of Two Formulations Of Moroctocog Alfa (AF-CC)

Pfizer

NCT01233440 COMPLETED

Safety and Pharmacokinetic Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein in Subjects With Hemophilia B

CSL Behring

NCT05936580 RECRUITING

Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery

Octapharma

NCT05935358 RECRUITING

Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study

Octapharma

NCT06752850 ACTIVE NOT RECRUITING

A Study to Investigate the Course of Synovial Hypertrophy in Patients With Haemophilia A on Efanesoctocog Alfa Prophylaxis

Swedish Orphan Biovitrum

NCT05181618 ACTIVE NOT RECRUITING

A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis

Hoffmann-La Roche

NCT06940830 RECRUITING

Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog Alfa

Swedish Orphan Biovitrum

NCT07406139 RECRUITING

PCC Treatment for Hemophilia Patients With Inhibitor（2022PCC-A）

Institute of Hematology & Blood Diseases Hospital, China

NCT04647227 RECRUITING

SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors

American Thrombosis and Hemostasis Network

NCT06145373 RECRUITING

A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab

Sanofi

NCT07158606 NOT YET RECRUITING

Understanding Treatment Outcomes and Immunologic Mechanisms in Altuviiio Immune Tolerance Induction

Versiti Blood Health

NCT05849740 RECRUITING

An Exploratory Study of Cluster of Differentiation 38 (CD38) Monoclonal Antibody Combined Corticosteroid in Acquired Hemophilia A

Institute of Hematology & Blood Diseases Hospital, China

NCT06864975 RECRUITING

Assessing Different FVIII Doses and Frequencies in Immune Tolerance Induction (ITI) with ADVATE Among Hemophilia a Boys with Inhibitor (INITIATE Study)

Runhui WU

NCT05888870 RECRUITING

ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor

Institute of Hematology & Blood Diseases Hospital, China

NCT06320626 RECRUITING

Pharmacokinetic-guided Dosing of Emicizumab

Kathelijn Fischer

NCT04205175 ACTIVE NOT RECRUITING

A Study to Evaluate the Safest Dose Range for FEIBA in Hemophilia A Patients With Inhibitors on Emicizumab

Children's Hospital Los Angeles

NCT04690322 WITHDRAWN

POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies

University of Texas Southwestern Medical Center

NCT03384277 COMPLETED

Trial of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab

Institute of Hematology & Blood Diseases Hospital, China

NCT05036278 COMPLETED

Prophylaxis Regimen for Hemophilia A Patients

Bayer

NCT04565236 COMPLETED

A Post Approval Commitment Study to Gain More Information on How Safe and Effective KOVALTRY is in Chinese Children, Adolescents /Adults With Severe Hemophilia A

Bayer

NCT05856266 TERMINATED

An 18-month Low-interventional Study to Assess Joint Health in Haemophilia A and B Patients on Prophylaxis With Efmoroctocog Alfa or Eftrenonacog Alfa

Swedish Orphan Biovitrum

NCT03103542 COMPLETED

Study of rFVIIIFc for Immune Tolerance Induction (ITI) in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI Therapies

Swedish Orphan Biovitrum

NCT04784988 COMPLETED

Intensive Replacement Treatment in Haemophilia Patients With Synovitis

Federico II University

NCT04985682 COMPLETED

A Study of ADVATE in People With Hemophilia A in India

Baxalta now part of Shire

NCT04728217 COMPLETED

Health Related Quality of Life of Youth and Young Adults With Haemophilia A

The League of Clinical Research, Russia

NCT04085458 COMPLETED

Study to Gain More Information on How Safe and Effective Jivi Works in Patients With Severe Hemophilia A (Post-marketing Investigation)

Bayer

NCT05728528 COMPLETED

Impact of Moderate Intensity Physical Activities on PK-guided EHL FVIII Concentrates Prophylaxis Severe HA Patients

Chulalongkorn University

NCT03565237 COMPLETED

RIXUBIS PMS India (RIXUBIS PMS)

Baxalta now part of Shire

NCT05281185 COMPLETED

Clinical Outcomes of Low Dose PK-guided EHL FVIII Concentrates Versus Standard Prophylaxis in Severe Haemophilia A

Chulalongkorn University

NCT04286412 COMPLETED

Nonacog Alfa Prophylaxis And Treatment Of Bleeding Episodes In Previously Treated Patients With Hemophilia B

Pfizer

NCT03093480 COMPLETED

A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)

Bioverativ, a Sanofi company

NCT00666406 COMPLETED

Pharmacokinetic Comparison of Advate rAHF-PFM With Recombinate rAHF in Patients With Severe Hemophilia A

Baxalta now part of Shire

NCT00916032 COMPLETED

Pharmacokinetic Study of ADVATE 3000 IU in Previously Treated Patients With Severe Hemophilia A

Baxalta now part of Shire

NCT04396639 COMPLETED

Moroctocog Alfa (AF-CC) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Hemophilia A Patients

Pfizer

NCT02170402 COMPLETED

China ADVATE PTP Study

Baxalta now part of Shire

NCT01128881 COMPLETED

IMMUNINE Pre-Treatment Study

Baxalta now part of Shire

NCT03915080 COMPLETED

Optimizing the Use of Prophylaxis in Patients With Severe Haemophilia A

Lund University

NCT03361137 TERMINATED

Study of Emicizumab Prophylaxis in Participants With Hemophilia A With or Without Inhibitors Undergoing Minor Surgical Procedures

Genentech, Inc.

NCT03204539 TERMINATED

INdividualized ITI Based on Fviii(ATE) Protection by VWF

University of California, Davis

NCT03379974 COMPLETED

Exercise Versus DDAVP in Patients With Mild Hemophilia A

Nationwide Children's Hospital

NCT00950170 COMPLETED

Study of Safety And Efficacy Of ReFacto AF In Previously Untreated Hemophilia A Patients In The Usual Care Setting

Pfizer

NCT01064284 COMPLETED

Survey of Inhibitors in Plasma-Product Exposed Toddlers

Fondazione Angelo Bianchi Bonomi

NCT02336178 COMPLETED

Safety and Efficacy of Benefix in Patients With Hemophilia B in Usual Care Settings in China

Pfizer

NCT02492984 COMPLETED

PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia A

Pfizer

NCT00914459 COMPLETED

Study Evaluating Safety And Efficacy Of Moroctocog Alfa (AF-CC) In Previously Treated Hemophilia A Patients

Pfizer

NCT02727647 COMPLETED

Comparison of Different Prophylaxis Regimens for Moderate to Severe Hemophilia A Pediatric Patients

Chulalongkorn University

NCT01810666 COMPLETED

Prophylaxis Versus on Demand Treatment for Children With Hemophilia A

Bayer

NCT00884390 TERMINATED

Study Evaluating Safety Of Patients Switching To ReFacto AF In Usual Care Settings

Pfizer

NCT01748201 COMPLETED

Viscosupplementation in Patients With Hemophilic Arthropathy

University of Sao Paulo General Hospital

NCT00927667 COMPLETED

Joint Status in Subjects With Severe Hemophilia A in Relation to Different Treatment Regimens

Bayer

NCT00765726 TERMINATED

Study Evaluating The Safety Of Xyntha In Usual Care Settings

Pfizer

NCT00749476 COMPLETED

Study Evaluating BeneFIX in Patients With Haemophilia B, Previously Treated With Plasma Derived Factor IX

Wyeth is now a wholly owned subsidiary of Pfizer

Full Hemophilia Pipeline

Every sponsor, every trial across Phase 1–4. Sortable, filterable, exportable.

Unlock with Pro

Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only